Regulatory News:
Eurofins (Paris:ERF):
Financial highlights
Eurofins delivered a strong set of results in H1 2024:
- Total revenues of €3,419m represented a new record level for
the first half of a fiscal year, as Eurofins has now grown to
exceed its peak pandemic-driven revenue level, but without COVID-19
related revenues. The year-on-year increase was 6.5%, supported by
solid organic growth13 in the Core Business of 5.6% and a strong
pace of acquisitions, but restrained by FX headwinds (-0.5%). The
organic growth13 figure is not corrected for a slightly negative
working day effect as H1 2024 had 0.2 fewer working days than H1
2023. A 1–2-day positive working days impact is expected in H2
2024.
- Adjusted1 EBITDA3 of €757m (22.1% of revenues) was 18.3% higher
than the €640m (19.9% of revenues) achieved in H1 2023. This
improvement resulted from a combination of pricing attainment,
volume growth, and disciplined cost management, in particular
personnel expenses, consumables and building costs. All regions
demonstrated improvement in profitability.
- Net Profit7 increased year-on-year by 46% to €220m in H1 2024
vs €151m in H1 2023.
- Generation of Free Cash Flow before investment in owned sites16
increased by 171% from €125m in H1 2023 to €341m in H1 2024, thanks
to the increase in EBITDA3, continued capex discipline for
programmes related to capacity expansion, and improved net working
capital12 intensity.
- Free Cash Flow to the Firm10 increased 276% from €74m in H1
2023 to €279m in H1 2024.
- Eurofins’ balance sheet remains very solid at the end of June
2024:
- Financial leverage (net debt11 to last 12 months adjusted1
pro-forma EBITDA3) down to 1.9x at the end of June 2024 vs 2.0x at
the end of 2023 and well within its targeted range of
1.5-2.5x.
- Having carried out an early redemption of a €448m Eurobond on
19 June 2024, one month ahead of its maturity date on 25 July 2024,
Eurofins has no major financing requirements for the remainder of
2024. The next maturities are Schuldschein loans totalling €234m,
maturing in July and October 2025 respectively, and €400m in hybrid
capital with a first call date of 13 November 2025.
Strategic highlights
Eurofins companies continue to advance on their long-term
growth, digitalisation and innovation initiatives:
- In terms of M&A, the pace of acquisitions has been strong
so far this year.
- In H1 2024, Eurofins closed 15 business combinations that
generated FY 2023 pro-forma revenues of about €132m at a cost of
€246m, reflecting a sales multiple of 1.9x.
- Companies acquired in H1 2024 include Ascend Clinical, LLC, the
largest independent laboratory for kidney dialysis testing in the
United States, which further supports Eurofins’ efforts to provide
best-in-class testing care to patients in the renal and
transplantation fields.
- Eurofins added 45,000 m2 of net surface area to expand its
network in the first six months of 2024. Through a combination of
building projects, building purchases and acquisitions in the
M&A scope, offset by a decrease in leased surfaces, Eurofins
was able to increase its ownership proportion of the total net
floor area of its sites to 33.1% at the end of June 2024 vs 31.7%
at the end of 2023.
- The pace of start-up activity remained strong in H1 2024 as
Eurofins opened 18 new start-up laboratories and nine new blood
collection points (BCPs). The 319 start-ups and 76 BCPs launched
since 2000 have made material contributions to the overall organic
growth of the Group, accounting for 0.9% out of the 5.6% of organic
growth achieved in H1 2024.
- Eurofins companies continue to make meaningful contributions to
Testing for Life:
- Eurofins Genoma’s Genome-Wide Non-Invasive Prenatal Tests
(GW-NIPT) were recently acknowledged in a paper published in the
journal Prenatal Diagnosis as having extremely high clinical
utility.
- Eurofins Discovery launched DiscoveryAI SAFIRE, an advanced
platform for drug discovery that leverages proprietary datasets,
artificial intelligence (AI) and machine learning (ML) to predict
the ADMET (Absorption, Distribution, Metabolism, Excretion and
Toxicity) properties of molecules.
- Eurofins CDMO Alphora Inc. announced the completion of its
expansion of active pharmaceutical ingredient (API) capacity and
capabilities at its new API manufacturing facility in Mississauga,
Canada. This capacity expansion will allow Eurofins CDMO Alphora to
support existing and prospective partners to address expanding
therapeutic indications and meet the growing demand for emerging
therapies at clinical and commercial stages.
2024 to 2027 Objectives
- Eurofins does not provide guidance on future results. Depending
on long-term interest rate and inflation expectations, Eurofins
management sets multiyear targets (typically valid for 5 to 10
years) for its minimum hurdle rate for return on capital employed
on its investments (currently 16% after 3 years) and average
targets for annual organic growth over the period (currently 6.5%).
Eurofins develops unique levels of depth, breadth, quality and
speed of service for clients and overall efficiency and competitive
advantage through focussed 5-year investment programmes to create
unmatched laboratory and digital infrastructure in its chosen
markets, with increasingly global coverage.
- 2024 is the second year of the 2023-2027 programme. Objectives
for 2027 were shared on 1 March 2023. In addition, once a year when
publishing its annual results, Eurofins management also shares
objectives for the current year. Eurofins’ policy is not to update
these annual objectives unless very significant and unforeseen
changes occur. Objectives for FY 2024, which were announced at the
FY 2023 results presentation on 27 February 2024, and those for
2027, announced on 1 March 2023, thus remain unchanged.
€m
FY 2024
FY 2027
Revenues
€7.075bn – €7.175bn
Approaching €10bn
Adjusted1 EBITDA3
€1.525bn – €1.575bn
Margin: 24%
FCFF before investment in owned
sites16
€800m - €840m
Approaching €1.5bn
- The FY 2024 and FY 2027 objectives assume same average exchange
rates as in FY 2023 and zero contribution from COVID-19 clinical
testing and reagents. From FY 2024 to FY 2027, Eurofins targets
average organic growth13 of 6.5% p.a. and potential average
revenues from acquisitions of €250m p.a. over the period
consolidated at mid-year. In addition, Eurofins will remain prudent
with its acquisition strategy and only acquire businesses that meet
its objectives for return on capital employed.
- Similar to the achievement of an improved adjusted1 EBITDA3
margin in H1 2024 vs H1 2023, anticipated further improvements in
adjusted1 EBITDA3 margin in FY 2024 and towards the FY 2027
objective are underpinned by programmes that continue to align
pricing to cost inflation, as well as innovation, productivity,
digitalisation and automation initiatives, and better utilisation
of Eurofins’ state-of-the-art laboratory network.
- Eurofins continues to conduct reviews of some of its smaller
underperforming businesses.
- In the coming year, Eurofins expects to continue its high
intensity of start-up activities. Due to temporary losses related
to these start-ups, Separately Disclosed Items2 (SDI) at the
EBITDA3 level should remain at an elevated level of about €125m in
FY 2024. Thereafter, as newly initiated start-ups ramp up and
become profitable, the objective is that SDI2 at the EBITDA3 level
should decline gradually towards about 0.5% of revenues in
2027.
- Capital allocation for strategically important investments
remain key to Eurofins’ long-term value creation strategy.
Priorities for net operating capex in FY 2024 and in the mid-term
will continue to include start-ups in high-growth/high-return
areas, and the development and deployment of sector-leading
proprietary IT solutions. Capital allocation for net operating
capex is expected to be ca. €400m p.a.
- In addition, Eurofins will prioritise, if required, the
stepwise acquisition of sites owned by related parties, if decided
by a majority of its non-related shareholders, over the acquisition
of new sites from third parties. Investment in site ownership is
assumed to be around €200m p.a.
- Eurofins is fully committed to protecting the sustainability of
its balance sheet within its stated financial leverage objectives
with adequate headroom. It targets to maintain a financial leverage
of 1.5-2.5x in the mid-term period and less than 1.5x by FY
2027.
Comments from the CEO, Dr Gilles Martin:
“Though the first six months of 2024 remained clouded by
geopolitical and macroeconomic uncertainties, Eurofins companies
continued to deliver outstanding results in the areas that matter
most to our stakeholders: operational excellence, speed and quality
of service and innovation for our clients, financial performance
and sustainability for our shareholders, and continued investments
to create a great place to work for our leaders and staff in a
decentral entrepreneurial, fair and inclusive meritocratic
environment.
“In terms of financial performance and operational excellence,
in what historically has been the seasonally weakest semester of
the year, Eurofins achieved solid organic growth, setting a new
revenues record for a first half year and, even more impressively,
achieved a reported EBITDA3 margin of 20.9%, equivalent to a
year-on-year improvement of 260bps. This increase builds upon the
previously recorded year-on-year improvement achieved in H2 2023 vs
H2 2022 of 90bps of reported EBITDA3 margin. The first positive
impacts of Eurofins’ investment in building the best-in-class and
most digital laboratory network in its field are starting to be
felt now in the second year of its most recent 5-year investment
programme. In H1 2024, despite being at the peak investment
intensity of its digitalisation initiatives in 2024 and 2025,
Eurofins was able to reduce its financial leverage (net debt11 to
last 12 months adjusted1 pro-forma EBITDA3) and simultaneously make
large investments in M&A, laboratories buildings, capex,
start-ups, R&D and share buy-backs.
“We are further encouraged by progress in our digitalisation
initiatives. Development of a unique suite of IT solutions is
proving successful with deployment of the newest tools in several
pilot sites of our Life area of activity, with planned completion
of the remaining applications by the end of 2025 for most business
lines. This opens the path for groupwide deployment of these IT
solutions by the end of our 5-year investment programme in 2027,
though substantial benefits should already begin to be felt by
2026. Similarly, the building of a fully new state-of-the-art, more
decentral, secure, and resilient IT infrastructure will have made
large progress by the end of 2024 and should complete next year.
Beyond their large impact on capex, these two initiatives represent
very significant investments in operating expenses that should
significantly decline by 2026. The conclusion of these initiatives,
combined with the benefit of more modern, lean, streamlined and
effective digital tools, should further contribute to improving the
quality and speed of service to clients, reduce costs, and pave the
way for more systematic use of automation and AI solutions across
our network.
"Eurofins companies remain as committed as ever to continue to
deliver innovative, high-quality services and operational
excellence to our clients and financial performance to our
investors. Given this latest set of results and our ongoing
initiatives to further improve on the productivity and
digitalisation of our operations, I remain very confident in the
capabilities and motivation of Eurofins teams, not only to finish
this year strongly and achieve our FY 2024 profitability
objectives, but to sustain that momentum as we progress toward
achieving our FY 2027 objectives.”
Conference Call
Eurofins will hold a conference call with analysts and investors
today at 15:00 CEST to discuss the results and the performance of
Eurofins, as well as its outlook, and will be followed by a
questions and answers (Q&A) session.
Click here to Join Call >> From any device, click the link
above to join the conference call.
The following figures are extracts from the Condensed Interim
Consolidated Financial Statements and should be read in conjunction
with the Condensed Interim Consolidated Financial Statements and
Notes for the period ended 30 June 2024. The Half Year Report 2024
can be found on Eurofins’ website at the following link:
https://www.eurofins.com/investors/reports-and-presentations/
Table 1: Half Year 2024 Results Summary
H1 2024
H1 2023
+/- %
Adjusted
results
+/- %
Reported
results
In €m except otherwise stated
Adjusted1
results
Separately
disclosed
items2
Reported
results
Adjusted1
results
Separately
disclosed
items2
Reported
results
Revenues
3,419
-
3,419
3,209
-
3,209
+6.5%
+6.5%
EBITDA3
757
-43
714
640
-51
589
+18%
+21%
EBITDA3 margin (%)
22.1%
-
20.9%
19.9%
-
18.3%
+220 bp
+260 bp
EBITAS4
497
-65
432
397
-69
327
+25%
+32%
Net profit7
320
-100
220
261
-110
151
+23%
+46%
Basic EPS8 (€)
1.55
-0.54
1.01
1.23
-0.59
0.65
+26%
+57%
Net cash provided by operating
activities
530
333
+59%
Net capex9
252
259
-3%
Net operating capex
190
208
Net capex for purchase and
development of owned sites
62
51
Free Cash Flow to the Firm before
investment in owned sites16
341
125
+171%
M&A spend
246
83
+195%
Net debt11
2,863
2,588
+11%
Leverage ratio (net
debt11/pro-forma adjusted1 EBITDA3)
1.9x
2.0x (end FY 2023)
-0.1x
Note: Definitions of the alternative performance measures used
can be found at the end of this press release
Revenues of €3,419m increased year-on-year in H1 2024 by 6.5%,
supported by solid organic growth13 in the Core Business of 5.6% as
well as a strong pace of acquisitions, as Eurofins closed 15
business combinations with FY 2023 pro-forma revenues of €132m.
These effects more than compensated for the complete disappearance
of COVID-19 clinical testing and reagent revenues, which was small
but in the order of €20m in H1 2023.
Table 2: Organic Growth13 Calculation and Revenue
Reconciliation
In €m except
otherwise stated
H1 2023 reported revenues
3,209
+ H1 2023 acquisitions - revenue part not
consolidated in H1 2023 at H1 2023 FX rates
45
- H1 2023 revenues of discontinued
activities / disposals15
-18**
= H1 2023 pro-forma revenues (at H1 2023
FX rates)
3,237
+ H1 2024 FX impact on H1 2023 pro-forma
revenues
-15
= H1 2023 pro-forma revenues (at H1
2024 FX rates) (a)
3,222
H1 2024 organic scope* revenues (at H1
2024 FX rates) (b)
3,383
H1 2024 organic growth13 rate
(b/a-1)
5.0%***
H1 2024 acquisitions - revenue part
consolidated in H1 2024 at H1 2024 FX rates
36
H1 2024 revenues of discontinued
activities / disposals15
0
H1 2024 reported revenues
3,419
* Organic scope consists of all companies that were part of the
Group as at 01/01/2024. This corresponds to the 2023 pro-forma
scope ** Q1 2024 impacted by discontinuation15 of the OmniGraf
dual-biomarker rejection panel following revised billing guidance
by MolDX in the U.S. effective 1 April 2023 *** Not corrected for
the decline in COVID-19 related clinical testing and reagent
revenues and not adjusted for public working days
Table 3: Breakdown of Revenue by Operating Segment
€m
H1 2024
As % of
total
H1 2023
As % of
total
Y-o-Y
variation
%
Organic
growth13 in the
Core Business*
Europe
1,748
51%
1,622
51%
7.7%
5.6%
North America
1,311
38%
1,243
39%
5.5%
4.9%
Rest of the World
360
11%
344
11%
4.5%
7.9%
Total
3,419
100%
3,209
100%
6.5%
5.6%
* Excluding COVID-19 related clinical testing and reagent
revenues
Europe
- Reported revenues increased vs H1 2023 by €125m, primarily due
to solid organic growth of 5.6% in the Core Business.
- BioPharma Services in Europe experienced moderate growth in a
market environment characterised by diverse developments in the
first half of 2024. On the one hand, demand for BioPharma Product
Testing, Bioanalytical Services, Toxicology, and Medical Devices
Testing remained stable. On the other hand, Agroscience Services
continues to experience tepid demand growth mirroring the subdued
situation in the global seed and crop protection market and related
to uncertainty regarding regulatory requirements in Europe in
relation to registering new crop protection products. Meanwhile,
demand from customers for Discovery Services has begun to gradually
recover, though volumes still remain below peak levels. In terms of
profitability, volume growth, further implementation of pricing
initiatives and ongoing cost adaptation measures including
footprint optimisation have driven margin improvement.
- Following the challenging years of 2022 and 2023 due to the
persisting effects of inflation on consumer food prices, Food and
Feed Testing in Europe saw a recovery in growth in most countries
in the first half of 2024, supported by pricing attainment as well
as some volume increases driven by product development by food
producers. In parallel, Eurofins continued to implement initiatives
to control costs and boost efficiency, including capacity
optimisation through labour force adaptations and footprint
consolidation. Furthermore, Eurofins has continued to invest in
innovations to improve the productivity of its laboratories. These
large investments include technology, digitalisation and automation
initiatives, such as fully automated sample preparation systems and
the successful deployment of Eurofins’ internally developed
next-generation LIMS software in a number of pilot sites. These IT
solutions, as well as other related bespoke standardized
proprietary IT applications, should be fully deployed throughout
the region by the end of 2026 to replace a vast array of costly and
less-efficient legacy IT solutions.
- The Environment Testing business in Europe set new sales
records to start 2024, driven by market share gains on the back of
strong service and offerings across multiple countries, as well as
pricing initiatives. In terms of organic growth, while continued
pricing and commercial excellence initiatives were supportive,
volume increases in numerous activities ranging from water testing
to asbestos testing and anticipated regulation supporting increased
PFAS testing have been significant contributory factors. The strong
operational performance of the European Environment Testing
laboratories, the acceleration of ongoing lean and automation
programmes, digitalisation, and strong customer-focussed mindset
have supported growth and improved profitability across the
Eurofins Environment Testing network in Europe. Further
improvements are still expected from the continuation of already
engaged productivity programmes, including footprint
rationalisation, the completion of the roll-out of next-generation
LIMS to replace a diverse and costly set of legacy LIMS systems and
the accelerated ramp up of automation projects.
- The Clinical Diagnostics Business in Europe continued taking
measures in H1 2024 to improve its growth and profitability. The
expansion of blood collection point (BCP) coverage in France
continued as nine new BCPs were opened in H1 2024, adding to the 67
BCPs launched in France and Belgium during 2022 and 2023. In Spain,
operational improvements have resulted in a normalisation of growth
and improved profitability. Volumes of specialised testing services
such as clinical genetics and NIPT grew well. In terms of
operational performance, organisational changes made in 2023,
including changes in leadership and network rationalisation
following the end of COVID-19 testing, have helped to improve
profitability, while digitalisation initiatives are supporting
productivity. In terms of innovation, in a paper published in the
journal Prenatal Diagnosis on a study of 71,883 unselected clinical
cases of Genome-Wide Non-Invasive Prenatal Test (GW-NIPT), Eurofins
Genoma demonstrated the clinical utility of its expanded NIPT in
pregnancy management.
North America
- Reported revenues increased year-on-year by €69m, supported by
steady organic growth of 4.9% in the Core Business.
- BioPharma Services revenues in North America were resilient in
the first half of 2024. Promising development has been observed in
Discovery Services, which showed signs of recovery from the
challenging market conditions in 2022 and 2023. Demand and
pipelines in BioPharma Product Testing, and Central and
Bioanalytical Laboratories remained sound as clients continue to
invest in promising therapies across all modalities. Profitability
margins continue improving across most areas of the business,
supported by cost savings and measures to optimise personnel costs.
Investments in future growth opportunities continue to progress,
most notably Eurofins CDMO Alphora’s completion of its 3,300 square
foot pilot-scale biologics development facility with a scale-up
capacity of up to 200L for pre-clinical and phase I supply. In
addition, a new Drug Product Analytical Laboratory will launch,
increasing Eurofins CDMO Alphora’s footprint three-fold. Eurofins
CDMO Alphora also completed a 2,000L scale API manufacturing
facility, which will commence production in the second half of
2024, with capacity already sold via supply agreements. Eurofins
Discovery also continues to introduce new innovations such as
DiscoveryAI Safire, an AI tool that leverages proprietary datasets
launched in early 2024 as a valuable service to help pharmaceutical
clients accelerate their drug discovery timeline.
- The Food and Feed Testing business in North America continued
to grow strongly in H1 2024 supported by steady demand growth and
market share gains driven by new start-up microbiology laboratories
in Missouri and Nebraska to address the stringent turnaround time
requirements of meat and produce customers. Another noteworthy
development that has driven growth is Eurofins Food and Feed
Testing’s selection as one of three third-party testing
organisations to support Amazon’s requirement for certificates of
authenticity from sellers of dietary supplements on Amazon’s
platform. In addition to volume growth and mix enhancement due to
higher value-added testing, pricing attainment, rush pricing,
normalising inflation and higher productivity all contributed to
improving profitability.
- Eurofins Environment Testing in North America delivered strong
organic growth in H1 2024. Growth was underpinned by market share
gains and increased demand across all sectors of environment
testing. Eurofins operates the market leading PFAS Testing Service,
in terms of both processing capacity and capability, in the US.
Demand for PFAS testing was buoyant across all client groups –
regulators, industrials, consultancies, municipalities, federal and
state governments. Growth outperformance was supported by the
rollout of digitalisation initiatives including electronic chain of
custody (eCOC), internal process AI, and enhancement to myEOL
(Eurofins online), all of which assist process efficiency and
client tracking/retrieval of data online. In terms of
profitability, margin improvement was delivered through volume
growth, consumable cost controls, the rollout of microextraction to
reduce solvent usage and lower logistics costs, and efficiencies
gained from robotics and automation initiatives. The outlook for
profitable growth remains very positive as upgrades in one
California laboratory and two Texas laboratories come online to
extend processing capacity through H2 2024. Additionally, the
in-progress construction of a new, state-of-the-art full-service
environment testing laboratory in Chicago will help drive growth in
the years to come.
- During the reporting period, Eurofins closed the acquisition of
Ascend Clinical, LLC (“Ascend”). Operating a state-of-the-art
laboratory in Sunnyvale, California and employing 170 staff, Ascend
is the largest independent laboratory for kidney dialysis testing
in the United States. This acquisition further reinforces the
Eurofins network’s footprint in transplant testing and associated
renal care, broadening its clinical client base and growing its
exposure to this promising segment.
Rest of the World
- Core Business revenues were up 7.9% year-on-year on an organic
basis due to strong organic growth across many countries and
activities.
- After more muted business conditions in Asia due to softness in
consumer spending in many regions of the world related to high
inflation in 2023, demand from customers has gradually rebounded in
numerous countries, in particular in China. The Food and Feed
Testing, BioPharma Services and Clinical Diagnostics businesses
delivered robust growth across Asia. Start-ups in China, India and
Southeast Asia also contributed to growth, while Eurofins was able
to win numerous nominations in its Consumer Product Testing
business over its competitors due to advancements in new services
and supporting customers’ supply chain movements. However, demand
in the Advanced Material Sciences business remains tepid as the
semiconductor and electronics industry is currently in an inventory
correction cycle. On the other hand, demand from customers engaged
in semiconductor equipment and battery materials has been healthy.
From a profitability perspective, margins benefitted both from the
aforementioned strong growth as well as network optimisation
measures and targeted investment initiatives.
- In Australia, organic growth was fueled by national
infrastructure projects including those being undertaken in
preparation for the 2032 Olympics. Eurofins has also expanded its
PFAS testing capabilities in the region into New Zealand, to
complement existing offerings in Brisbane, Sydney, Melbourne and
Perth.
- In Latin America, Eurofins has made continued progress
regarding footprint optimisation. On the one hand, business
activities in Argentina are being wound down, while on the other
hand acquisitions have been concluded in Brazil and Colombia in
Food and Feed Testing, further expanding the network’s
footprint.
- In the Middle East, Ajal Laboratories continues to generate
good growth in its core Food and Feed Testing business, in
particular in the area of animal health. Eurofins is also expanding
its services in the clinical diagnostics sector in Saudi
Arabia.
Table 4: Breakdown of Revenue by Area of Activity
€m
H1 2024
As % of
total
H1 2023
As % of
total
Y-o-Y
variation %
Organic growth13
in the Core
Business*
Life
1,379
40%
1,257
39%
9.8%
7.9%
BioPharma
1,000
29%
976
30%
2.5%
2.6%
Diagnostic Services &
Products
690
20%
652
20%
5.9%
4.5%
Consumer & Technology
Products Testing
349
10%
325
10%
7.3%
7.5%
Total
3,419
100%
3,209
100%
6.5%
5.6%
* Excluding COVID-19 related clinical testing and reagent
revenues
Life (consisting of Food and Feed
Testing, Agro Testing and Environment Testing)
- Food and Feed Testing in Europe saw a recovery in growth in the
first half of 2024, supported by pricing attainment as well as some
volume increases driven by product development by food
producers.
- The Food and Feed Testing business in North America continued
to grow strongly in H1 2024 driven by steady demand growth and
market share gains.
- In Rest of the World, Food and Feed Testing delivered robust
growth across numerous countries in Asia and the Middle East.
- The Environment Testing business in Europe set new sales
records to start 2024, driven by market share gains on the back of
strong service and offerings across multiple countries, as well as
pricing initiatives.
- Eurofins Environment Testing in North America delivered strong
organic growth in H1 2024. Growth was underpinned by market share
gains and increased demand across all sectors of Environment
Testing.
- Environment Testing in Rest of the World experienced organic
growth in Australia, fueled by national infrastructure projects
including those being undertaken in preparation for the 2032
Olympics. Eurofins has also expanded its PFAS testing capabilities
in the region into New Zealand, to complement existing offerings in
Brisbane, Sydney, Melbourne and Perth.
Biopharma (consisting of BioPharma
Services, Agrosciences, Genomics and Forensic
Services)
- BioPharma Services in Europe experienced moderate growth in a
market environment characterised by diverse developments in the
first half of 2024. Demand for BioPharma Product Testing,
Bioanalytical Services, Toxicology, and Medical Devices Testing
remained stable. Meanwhile, demand from customers for Discovery
Services has begun to gradually recover, though volumes still
remain below peak levels. Professional Scientific Services® (PSS)
was able to outgrow the market by winning new clients.
- BioPharma Services revenues in North America were resilient in
the first half of 2024. Promising developments were observed in
Discovery Services, which showed signs of recovery from the
challenging market conditions in 2022 and 2023. Demand and
pipelines in BioPharma Product Testing and Central and
Bioanalytical Laboratories remained sound as clients continue to
invest in promising therapies across all modalities.
- BioPharma Services in Asia delivered robust growth across
numerous countries.
- Agroscience Services continues to experience tepid demand
growth mirroring the subdued situation in the global seed and crop
protection market and thus remains a very challenged area of
activity with limited improvement in sight.
- Eurofins’ Genomics business line continues its post-COVID pivot
towards activities related to genes, plasmids, biopharma and
large-scale, high-throughput end market applied genomics
solutions.
Diagnostic Services & Products
(consisting of Clinical Diagnostics Testing and In Vitro
Diagnostics (IVD) Solutions)
- The Clinical Diagnostics Business in Europe realised
improvements in growth in H1 2024. The expansion of blood
collection point (BCP) coverage in France continued as nine new
BCPs were opened in H1 2024, adding to the 67 BCPs launched in
France and Belgium during 2022 and 2023. In Spain, operational
improvements have resulted in a normalisation of growth and
improved profitability. Specialised testing services such as
clinical genetics and NIPT have also been growing well.
- During the reporting period, Eurofins closed the acquisition of
Ascend Clinical, LLC (“Ascend”). Operating a state-of-the-art
laboratory in Sunnyvale, California and employing 170 staff, Ascend
is the largest independent laboratory for kidney dialysis testing
in the United States.
Consumer & Technology Products
Testing (consisting of Consumer Product Testing and Advanced
Material Sciences)
- After more muted business conditions in Asia due to softness in
consumer spending in many regions of the world related to high
inflation in 2023, demand from customers for Consumer Product
Testing has gradually rebounded in numerous countries, in
particular in China.
- Eurofins was able to win numerous nominations in its Consumer
Product Testing business over its competitors due to advancements
in new services supporting customers’ supply chain movements.
- Demand in the Advanced Material Sciences business remains tepid
as the semiconductor and electronics industry is currently in an
inventory correction cycle. On the other hand, demand from
customers engaged in semiconductor equipment and battery materials
has been healthy.
Infrastructure Programme
As part of its strategy to lease less and own more of its
strategic sites, Eurofins has added, in the first six months of
2024, a total of 37,000 m² of laboratory, office, and storage space
through the delivery of building projects as well as building
purchases, while decreasing its leased surfaces by 12,000 m².
Through acquisitions in the M&A scope, Eurofins has added an
additional surface of 20,000 m². Overall, this has resulted in a
net surface increase of 45,000 m² leading to a total net floor area
of 1,779,000 m². In terms of ownership, the proportion of net floor
area owned by Eurofins as at 30 June 2024 reached 33.1%, a
substantial increase compared to the 31.7% owned by Eurofins at the
end of 2023. This growth has been supported by the following
projects, among others.
To support the long-term development of BioPharma Services
businesses in Asia, Eurofins Advinus began utilising a portion of
its new 20,000 m² facility in Bangalore, India. The infrastructure
fitout of the entire facility is set to be completed by the end of
2024, with state-of-the-art bioanalytical laboratories to be
completed in 2025. The facility will enable Eurofins Advinus to
offer end-to-end drug development services and solutions to its
clients. The facility effectively utilises natural lighting,
ventilation, spacious building circulation and attractive
landscaping to provide an outstanding work environment.
In Louisville, a new two-storey 6,500 m² facility has been
successfully completed for Eurofins Genomics. The site is located
on 3.63 acres of land adjacent to an existing Eurofins laboratory
site. The new strategic Eurofins site will employ approximately 100
personnel and will support the expansion of production capacity for
oligonucleotides, in alignment with the global strategy of Eurofins
Genomics. The laboratory boasts state-of-the-art lean design and
accommodates specific market requirements, such as ensuring
separation between research use only (RUO) and good manufacturing
practice (GMP) production from start to finish. This mitigates the
risk of cross contamination between sequences, which is critical
for molecular diagnostics and clinical companies developing
commercial assays.
In response to increasing demand for PFAS testing in drinking
water, a new 650m² space dedicated to PFAS testing was opened in
South Bend, Indiana. The laboratory is located within Eurofins’
existing water testing facility at the location and supports an
increase in PFAS testing capacity for drinking water for Eurofins
Environment Testing USA clients.
In Moss, Norway, Eurofins Food and Feed Testing Norway AS has
consolidated its operations into a newly renovated 600 m²
state-of-the-art microbiology laboratory employing lean design
principles.
In Tamworth, UK, a large 5,000 m² laboratory and office facility
has just been completed following a 2-year long renovation. The
facility will house Eurofins Forensic Services’ operations, which
were previously located on a smaller, leased site. The Tamworth
laboratory will be capable of state-of-the-art DNA recovery, drug
analysis and elemental analysis to complement projects performed by
other Eurofins Forensic Services teams in Warrington and Feltham.
In addition, the facility provides office space for teams of expert
reporters and commercial functions for Workplace Drug Testing. The
strategic site also contains conferencing facilities and warehouse
space and provides ample space for potential future expansion.
For the remainder of 2024 and for 2025, Eurofins is planning to
add 99,000 m² of laboratory and operational space through building
projects, acquisitions, new leases and consolidation of sites, as
well as completing the renovation of 21,000 m² of its current sites
to bring them to the highest standard.
Financial Review
Reported EBITDA3 improved by 21% year-on-year to €714m in H1
2024. In terms of Reported EBITDA3 as a proportion of revenues, the
margin improved year-on-year by 260bps from 18.3% to 20.9%.
Table 5: Breakdown of Reported EBITDA3 by Operating
Segment
€m
H1 2024
Rep. EBITDA3
margin %
H1 2023
Rep. EBITDA3
margin %
Y-o-Y
variation %
Europe
292
16.7%
217
13.4%
+34%
North America
356
27.1%
313
25.2%
+14%
Rest of the World
84
23.4%
66
19.3%
+27%
Other*
-18
-8
Total
714
20.9%
589
18.3%
+21%
*Other corresponds to Group service functions
In Europe, reported EBITDA3 margins improved substantially by
330bps vs H1 2023 to 16.7% of revenues mainly due to pricing
attainment, volume growth and cost management actions which
together enabled a year-on-year decrease in personnel expenses by
ca. 150bps, while costs of purchased materials and services
decreased by ca. 180bps year-on-year, especially in the categories
of consumables and building costs. Margin improvement was
particularly strong in the DACH region, but also in France, which
remains slightly accretive to European margins. Margins also
expanded year-on-year in North America by 190bps, reaching 27.1% of
its revenues in the period, driven by volume growth and
productivity measures which resulted in year-on-year decreases in
personnel expenses by ca. 130bps and purchased materials and
services (comprised especially of consumables) by ca. 60bps. The
greatest increase in margins occurred in Rest of the World, which
saw H1 2024 reported EBITDA3 margins step up by 410bps vs the
prior-year period to 23.4% of revenues, thanks to equal
contributions from volume growth, price increases and productivity
measures.
Adjusted1 EBITDA3 was €757m in H1 2024, representing an
adjusted1 EBITDA3 margin of 22.1% and a margin improvement of
220bps vs H1 2023. The substantial improvement was achieved in part
from the readjustment of the Eurofins organisation to the
post-pandemic situation initiated in 2023 as well as through
pricing adaptations and cost efficiency initiatives, in particular
related to personnel expenses, consumables and building costs.
Table 6: Separately Disclosed Items2
In €m except otherwise stated
H1 2024
H1 2023
One-off costs from integrations,
reorganisations and discontinued operations, and other
non-recurring income and costs
-18
-12
Temporary losses and other costs
related to network expansion, start-ups and new acquisitions in
significant restructuring
-25
-39
EBITDA3 impact
-43
-51
Separately Disclosed Items2 (SDI) at the EBITDA3 level decreased
year-on-year to €43m (equivalent to 6% of reported EBITDA3) and
comprised:
- One-off costs from integrations, reorganisations and
discontinued operations, and other non-recurring income and costs
of €18m that are linked to ongoing integrations and
reorganisations, especially in Germany and France.
- Temporary losses and other costs related to network expansion,
start-ups and new acquisitions in significant restructuring
totalled €25m. The reduction in this figure was due to improved
profitability year-on-year in many start-up activities, most
notably in the In Vitro Diagnostic (IVD) and Genomics businesses
that are pivoting to new markets and activities post-COVID-19.
Conversely, start-up losses related to Clinical Diagnostics
continued, including the ongoing impact on Transplant Genomics Inc.
in the U.S. related to a billing article concerning Medicare
reimbursement which became effective on 31 March 2023.
Depreciation and amortisation (D&A), including expenses
related to IFRS 16, increased by 8% year-on-year to €282m. As a
percentage of revenues, D&A stood at 8.2% of Group revenues in
H1 2024, the same ratio as in H1 2023.
Net finance costs amounted to €69m in H1 2024, a sizable
increase compared to €42m in H1 2023. On the one hand, financial
income increased to €14.9m in H1 2024 vs €5.5m in H1 2023 thanks to
higher average excess cash (€740m in H1 2024 vs €517m in H1 2023)
bearing higher average interest rates, progress in cash
centralisation through cash pooling and a shift to banking partners
offering better remuneration of positive balances. On the other
hand, the increase in finance costs was driven by higher interest
expenses for bonds, in particular from the €600m of senior
unsecured Eurobonds issued in August 2023 and due in September 2030
that bears an annual fixed rate coupon of 4.75%, but also a net
foreign exchange loss of €7.1m related to the appreciation of USD,
partially offset by the depreciation of JPY vs EUR (H1 2023: net
foreign exchange gain of €11.4m). Overall, Eurofins’ average
interest rate on its financial borrowings in H1 2024 was
approximately 3.5%.
The income tax expense increased from €69m in H1 2023 to €81m in
H1 2024, a year-on-year increase of 18%. However, this increase was
below the 37% increase in profit before income taxes (€220m in H1
2023 vs €301m in H1 2024) due to the decrease in the tax rate from
31.4% in H1 2023 to 27.0% in H1 2024.
Reported net profit7 stood at €220m (6.4% of revenues and 46%
higher than €151m in H1 2023), resulting in a total reported basic
EPS8 of €1.01. Adjusted1 net profit7 stood at €320m compared to
€261m in H1 2023, resulting in total adjusted1 basic EPS8 of €1.55
in H1 2024.
Cash Flow &
Financing
Table 7: Cash Flows Reconciliation
€m
H1 2024
reported
H1 2023
reported
Y-o-Y
variation
Y-o-Y
variation %
Net cash provided by operating
activities
530
333
+197
+59%
Net capex9 (i)
-252
-259
+7
+3%
Net operating capex (includes
LHI)
-190
-208
+18
+9%
Net capex for purchase and
development of owned sites
-62
-51
-11
-22%
Free Cash Flow to the Firm before
investment in owned sites16
341
125
+215
+171%
Free Cash Flow to the Firm10
279
74
+205
+276%
Acquisitions spend and other
investments (ii)
-246
-83
-163
Proceeds from disposals of
subsidiaries, net (iii)
0
8
-8
Other (iv)
14
5
+8
Net cash provided by investing
activities (i) + (ii) + (iii) + (iv)
-484
-329
-155
-47%
Net cash provided by financing
activities
-588
205
-793
Net increase / (decrease) in
Cash and cash equivalents and bank overdrafts
-540
198
-739
Cash and cash equivalents at
end of period and bank overdrafts
681
682
-1
0%
Net cash provided by operating activities increased in H1 2024
to €530m vs €333m in H1 2023. Net working capital12 stood at 6.3%
of the Group’s revenues at the end of June 2024, a decrease of
50bps vs 6.8% at the end of June 2023 (calculated as a percentage
of last quarter revenues times four). The year-on-year improvement
resulted from a decrease in Days of Sales Outstanding (59 in H1
2024 vs 60 in H1 2023) and an increase in Days of Payables
Outstanding (58 in H1 2024 vs 56 in H1 2023).
Cash generation more than adequately financed net capex9 of
€252m in H1 2024 vs €259m in H1 2023. After considering these
investments, Free Cash Flow to the Firm10 (FCFF) was €279m in H1
2024 vs €74m in H1 2023. Cash conversion (FCFF10 / Reported
EBITDA3) improved strongly from 13% in H1 2023 to 39% in H1
2024.
Net capex9 included investments as part of Eurofins’ programmes
to own its laboratory sites, which totalled €62m in H1 2024 vs €51m
in H1 2023. Excluding these investments, FCFF before investment in
owned sites16 was €341m in the reporting period, a substantial
improvement vs €125m in the prior year period.
During the first six months of 2024, the Group completed 15
business combinations including 9 acquisitions of legal entities
and 6 acquisitions of assets. Net cash outflow on acquisitions
completed during the period and in previous years (in case of
payment of deferred considerations) amounted to €246m.
As part of its share buy-back programme, Eurofins allocated
€47.7m to repurchase 910,000 of its own shares in H1 2024 at an
average price of €52.40, representing 0.47% of its share capital.
Note that the cash flow impact in H1 2024 of €30m also includes
inflows received from the exercise of stock options and outflows
related to the liquidity contract but excludes the settlement of
share repurchases performed in the final days of June 2024.
The combination of FCFF10 as well as the aforementioned
acquisitions and share buy-backs resulted in a net debt11 figure of
€2,863m at the end of June 2024. The corresponding leverage (net
debt11/last 12 months proforma adjusted1 EBITDA3) was 1.9x, an
improvement of 0.1x vs the end of December 2023, and within
Eurofins’ 1.5x-2.5x target range. Furthermore, having carried out
an early redemption of a €448m Eurobond on 19 June 2024, one month
ahead of its maturity date on 25 July 2024, Eurofins has no major
financing requirements for the remainder of 2024. The next
maturities are Schuldschein loans totalling €234m maturing in July
and October 2025 respectively, and €400m in hybrid capital with a
first call date of 13 November 2025. Eurofins also possesses a
solid overall liquidity position, which includes a cash position of
€681m as at 30 June 2024 as well as access to over €1bn of
committed, undrawn mid-term (3-5 years) bilateral bank credit
lines.
Start-up Programme
In the first half of 2024, the Group opened 18 new start-up
laboratories and 9 new start-up blood collection points (BCPs). In
total, the 319 start-ups and 76 BCPs launched since 2000 have made
material contributions to the overall organic growth of the Group,
accounting for 0.9% out of the 5.6% organic growth achieved in the
Core Business in H1 2024. The adjusted1 EBITDA3 margin of start-ups
initiated between 2000-2018 are almost in line with the Group’s
margin, while the total margin of start-ups initiated since 2019
remains dilutive to the Group’s margin.
Of the 319 start-ups and 76 BCPs the Group has launched since
2000, 58% are located in Europe, 15% in North America and 28% in
the Rest of the World, with a significant number in high growth
regions in Asia. By area of activity, 36% are in Life (consisting
of Food and Feed Testing, Agro Testing and Environment Testing),
18% are in BioPharma (consisting of BioPharma Services,
Agrosciences, Genomics and Forensic Services), 37% in Clinical
Diagnostics Services and Products (consisting of Clinical
Diagnostics Testing and In Vitro Diagnostics (IVD) Solutions) and
8% in Consumer & Technology Products Testing (consisting of
Consumer Product Testing and Advanced Material Sciences).
Acquisitions
During the first six months of 2024, the Group completed 15
business combinations, made up of 9 acquisitions of legal entities
and 6 acquisitions of assets. These companies/activities have been
fully consolidated from the date the Group took control over these
entities. For the year ended 31 December 2023, these entities
generated revenues of about €132m.
Post-Closing Events
Since 1 July 2024, Eurofins has completed 4 small business
combinations, one in Europe, one in North America and two in Rest
of the World. The total annual revenues of these acquisitions
amounted to over €14m in 2023 for an aggregate acquisition price of
ca. €22m. These acquisitions employ more than 200 employees.
On 16 July 2024, a new stock option plan (1,530,729 options) and
a new Restricted Stock Unit (RSU) plan (106,962 RSUs) were granted,
representing ca. 0.85% of the number of shares issued as of 30 June
2024.
Summary financial statements:
Table 8: Summarised Income Statement
H1 2024
H1 2023
In €m except otherwise stated
Reported
Results
Reported
Results
Revenues
3,419
3,209
Operating costs, net
-2,705
-2,621
EBITDA3
714
589
EBITDA3 Margin
20.9%
18.3%
Depreciation and amortisation
-282
-262
EBITAS4
432
327
Share-based payment charge and
acquisition-related expenses, net5
-63
-66
Gain/(loss) on disposal
-
-
EBIT6
369
262
Finance income
15
17
Finance costs
-84
-59
Share of profit of associates
1
0
Profit before income taxes
301
220
Income tax expense
-81
-69
Net profit7 for the
period
220
151
Attributable to:
Owners of the Company and hybrid
capital investors
221
152
Non-controlling interests
-1
-1
Earnings per share (basic) in
EUR
- Total
1.14
0.79
- Attributable to owners of the
Company8
1.01
0.65
- Attributable to hybrid capital
investors
0.13
0.14
Earnings per share (diluted) in
EUR
- Total
1.13
0.76
- Attributable to owners of the
Company
1.00
0.63
- Attributable to hybrid capital
investors
0.13
0.14
Basic weighted average shares
outstanding - in millions
193.0
192.9
Diluted weighted average shares
outstanding - in millions
195.2
198.2
Table 9: Summarised Balance Sheet
30 June
2024
31 December
2023
In €m except otherwise stated
Reported
Results
Reported
Results
Property, plant and equipment
2,440
2,297
Goodwill
4,718
4,551
Other intangible assets
832
796
Investments in associates
5
5
Non-current financial assets
80
78
Deferred tax assets
108
94
Total non-current
assets
8,184
7,822
Inventories
142
139
Trade receivables
1,084
1,073
Contract assets
333
308
Prepaid expenses and other
current assets
252
203
Current income tax assets
117
118
Derivative financial instruments
assets
4
4
Cash and cash equivalents
681
1,221
Total current assets
2,613
3,066
Total assets
10,797
10,889
Share capital
2
2
Treasury shares
-86
-55
Hybrid capital
1,000
1,000
Other reserves
1,601
1,601
Retained earnings
2,498
2,394
Currency translation reserve
228
136
Total attributable to owners of
the Company
5,243
5,078
Non-controlling interests
54
60
Total shareholders'
equity
5,297
5,137
Borrowings
3,373
3,326
Deferred tax liabilities
117
110
Amounts due for business
acquisitions
82
107
Employee benefit obligations
65
66
Provisions
21
21
Total non-current
liabilities
3,658
3,630
Borrowings
171
601
Interest due on borrowings and
earnings due on hybrid capital
112
59
Trade accounts payable
589
600
Contract liabilities
175
193
Current income tax
liabilities
22
27
Amounts due for business
acquisitions
62
36
Provisions
26
21
Other current liabilities
685
585
Total current
liabilities
1,842
2,122
Total liabilities and
shareholders' equity
10,797
10,889
Table 10: Summarised Cash Flow Statement
H1 2024
H1 2023
In €m except otherwise stated
Reported
Reported
Cash flows from operating
activities
Profit before income taxes
301
220
Depreciation and amortisation
282
262
Share-based payment charge and
acquisition-related expenses, net
63
66
Gain/(loss) on disposal of
subsidiaries, net
-
-
Finance income and costs, net
68
43
Share of profit from
associates
-1
0
Transactions costs and income
related to acquisitions
-4
-3
Changes in provisions and
employee benefit obligations
-1
-11
Other non-cash effects
-1
1
Change in net working
capital12
-78
-154
Cash generated from
operations
629
422
Income taxes paid
-98
-88
Net cash provided by operating
activities
530
333
Cash flows from investing
activities
Purchase of property, plant and
equipment
-218
-228
Purchase, capitalisation of
intangible assets
-36
-35
Proceeds from sale of property,
plant and equipment
2
4
Net capex9
-252
-259
Free cash Flow to the Firm10
279
74
Acquisitions of subsidiaries,
net
-246
-83
Proceeds from disposals of
subsidiaries, net
0
8
Acquisitions of investments,
financial assets and derivative financial instruments, net
-1
0
Interest received
15
5
Net cash used in investing
activities
-484
-329
Cash flows from financing
activities
Proceeds from issuance of share
capital
-
8
Purchase of treasury shares, net
of gains
-30
-37
Proceeds from issuance of hybrid
capital
-
594
Repayment of hybrid capital
-
-183
Proceeds from borrowings
30
17
Repayment of borrowings
-464
-81
Repayment of lease
liabilities
-93
-85
Dividends paid to shareholders
and non-controlling interests
-1
-1
Earnings paid to hybrid capital
investors
-
-9
Interests and premium paid
-31
-19
Net cash provided by financing
activities
-588
205
Net effect of currency
translation on cash and cash equivalents and bank overdrafts
1
-11
Net increase in cash and cash
equivalents and bank overdrafts
-540
198
Cash and cash equivalents and
bank overdrafts at beginning of period
1,221
483
Cash and cash equivalents and
bank overdrafts at end of period
681
682
1
Adjusted results – reflect the
ongoing performance of the mature14 and recurring activities
excluding “separately disclosed items”2.
2
Separately disclosed items –
include one-off costs from integration and reorganisation,
discontinued operations, other non-recurring income and costs,
temporary losses and other costs related to network expansion,
start-ups and new acquisitions undergoing significant
restructuring, share-based payment charge5, impairment of goodwill,
amortisation of acquired intangible assets and negative goodwill,
gains/losses on disposal of businesses and transaction costs
related to acquisitions as well as income from reversal of such
costs and from unused amounts due for business acquisitions, net
finance costs related to borrowing and investing excess cash and
one-off financial effects (net of finance income), net finance
costs related to hybrid capital and the related tax effects.
3
EBITDA – Earnings before
interest, taxes, depreciation and amortisation, share-based payment
charge and acquisition-related expenses, net5 and gain and loss on
disposal of subsidiaries, net.
4
EBITAS – EBITDA less depreciation
and amortisation.
5
Share-based payment charge and
acquisition-related expenses, net – Share-based payment charge,
impairment of goodwill, amortisation of acquired intangible assets,
negative goodwill, and transaction costs related to acquisitions as
well as income from reversal of such costs and from unused amounts
due for business acquisitions.
6
EBIT – EBITAS less Share-based
payment charge, acquisition-related expenses, net5 and gain and
loss on disposal of subsidiaries, net.
7
Net Profit – Net profit for
owners of the Company and hybrid capital investors before
non-controlling interests.
8
Basic EPS – basic earnings per
share attributable to owners of the Company.
9
Net capex – Purchase,
capitalisation of intangible assets, property, plant and equipment
less capex trade payables change of the period and proceeds from
disposals of such assets.
10
Free Cash Flow to the Firm – Net
cash provided by operating activities, less Net capex9.
11
Net debt – Current and
non-current borrowings, less cash and cash equivalents.
12
Net working capital –
Inventories, trade receivables and contract assets, prepaid
expenses and other current assets less trade accounts payable,
contract liabilities and other current liabilities excluding
accrued interest receivable and payable.
13
Organic growth for a given period
(Q1, Q2, Q3, Half Year, Nine Months or Full Year) – non-IFRS
measure calculating the growth in revenues during that period
between 2 successive years for the same scope of businesses using
the same exchange rates (of year Y) but excluding discontinued
operations.
For the purpose of organic growth
calculation for year Y, the relevant scope used is the scope of
businesses that have been consolidated in the Group's income
statement of the previous financial year (Y-1). Revenue
contribution from companies acquired in the course of Y-1 but not
consolidated for the full year are adjusted as if they had been
consolidated as of 1st January Y-1. All revenues from businesses
acquired since 1st January Y are excluded from the calculation.
14
Mature scope: excludes start-ups
and acquisitions in significant restructuring. A business will
generally be considered mature when: i) The Group’s systems,
structure and processes have been deployed; ii) It has been
audited, accredited and qualified and used by the relevant
regulatory bodies and the targeted client base; iii) It no longer
requires above-average annual capital expenditures, exceptional
restructuring or abnormally large costs with respect to current
revenues for deploying new Group IT systems. The list of entities
classified as mature is reviewed at the beginning of each year and
is relevant for the whole year.
15
Discontinued activities /
divestments: discontinued operations are a component of the Group’s
Core Business or product lines that have been disposed of, or
liquidated; or a specific business unit or a branch of a business
unit that has been shut down or terminated, and is reported
separately from continued operations. For more information, please
refer to Note 2.26 of the Consolidated Financial Statements for the
year ended 31 December 2023 and to Note 2.3 and Note 2.6 of the
Interim Condensed Consolidated Financial Statements for the period
ended 30 June 2024.
16
FCFF before investment in owned
sites: FCFF10 less Net capex9 spent on purchase of land, buildings
and investments to purchase, build or modernise owned
sites/buildings (excludes laboratory equipment and IT).
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific S.E.
network of independent companies believes that it is a global
leader in food, environment, pharmaceutical and cosmetic product
testing and in discovery pharmacology, forensics, advanced material
sciences and agroscience contract research services. It is also one
of the market leaders in certain testing and laboratory services
for genomics, and in the support of clinical studies, as well as in
biopharma contract development and manufacturing. It also has a
rapidly developing presence in highly specialised and molecular
clinical diagnostic testing and in-vitro diagnostic products.
With ca. 62,000 staff across a decentralised and entrepreneurial
network of more than 900 laboratories in over 1,000 companies in 62
countries, Eurofins offers a portfolio of over 200,000 analytical
methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of a wide range of
products, as well as providing innovative clinical diagnostic
testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
The Eurofins network has grown very strongly since its inception
and its strategy is to continue expanding its technology portfolio
and its geographic reach. Through R&D and acquisitions, its
companies draw on the latest developments in the field of
biotechnology and analytical chemistry to offer their clients
unique analytical solutions.
Shares in Eurofins Scientific S.E. are listed on the Euronext
Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg
ERF FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723918507/en/
For more information, please visit www.eurofins.com or
contact:
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
Enerplus (NYSE:ERF)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Enerplus (NYSE:ERF)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024